⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

Official Title: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts

Study ID: NCT02933489

Conditions

Asymptomatic

Study Description

Brief Summary: This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a computer and used to create detailed pictures of the breast in less than 10 minutes. These pictures can show the difference between normal and diseased tissue. Digital tomosynthesis mammography is a procedure that uses multiple x-rays pictures of each breast to produce a 3-dimensional rendering of the entire breast. Combined screening with abbreviated breast MRI and digital tomosynthesis mammography may be a better method to screen women with dense breasts.

Detailed Description: PRIMARY OBJECTIVES: I. To compare the rates of detection of invasive cancers between the initial abbreviated breast (AB)-magnetic resonance (MR) and digital tomosynthesis mammography (DBT). SECONDARY OBJECTIVES: I. To compare the positive predictive value (PPV) of biopsies, call back rates, and short-term follow up rates after AB-MR and DBT on both the initial and 1 year follow up studies. II. To estimate and compare the sensitivity and specificity of AB-MR and DBT, using the 1 year follow up to define a reference standard. III. To compare patient-reported short-term quality of life related to diagnostic testing with AB-MR and DBT using the Testing Morbidities Index. IV. To compare willingness to return for testing with AB-MRI versus (vs) DBT within the recommended screening interval and explore factors associated with willingness to return for screening. V. To compare the tumor biologies of invasive cancers and ductal carcinoma in situ (DCIS) detected on AB-MR and DBT. VI. To estimate the incident cancer rate during 3 years following the year-1 AB-MR/DBT when patients return to standard screening. OUTLINE: Participants are randomized to 1 of 2 arms. ARM A (DBT, AB-MR): Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year. ARM B (AB-MR, DBT): Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1 year. After completion of study, patients are followed up at every 6 months for 3 years.

Keywords

Eligibility

Minimum Age: 40 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: Yes

Locations

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

Huntington Memorial Hospital, Pasadena, California, United States

The Women's Imaging Center, Denver, Colorado, United States

Radiology Imaging Associates, Englewood, Colorado, United States

Norwalk Hospital, Norwalk, Connecticut, United States

Helen F Graham Cancer Center, Newark, Delaware, United States

Boca Raton Regional Hospital, Boca Raton, Florida, United States

Mayo Clinic in Florida, Jacksonville, Florida, United States

Diagnostic Center for Women LLC, Miami, Florida, United States

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Queen's Medical Center, Honolulu, Hawaii, United States

Northwestern University, Chicago, Illinois, United States

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

Clinical Radiologists SC, Springfield, Illinois, United States

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

The Community Hospital, Munster, Indiana, United States

Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States

University of Kansas Cancer Center, Kansas City, Kansas, United States

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States

Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Lahey Hospital and Medical Center, Burlington, Massachusetts, United States

Mercy Health Saint Mary's, Grand Rapids, Michigan, United States

West Michigan Cancer Center, Kalamazoo, Michigan, United States

Essentia Health Cancer Center, Duluth, Minnesota, United States

Mayo Clinic, Rochester, Minnesota, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States

Montefiore Medical Center-Einstein Campus, Bronx, New York, United States

Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Roswell Park Cancer Institute, Buffalo, New York, United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States

Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States

Aultman Health Foundation, Canton, Ohio, United States

Case Western Reserve University, Cleveland, Ohio, United States

UHHS-Westlake Medical Center, Westlake, Ohio, United States

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Geisinger Medical Center, Danville, Pennsylvania, United States

Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Rhode Island Hospital, Providence, Rhode Island, United States

Spartanburg Medical Center, Spartanburg, South Carolina, United States

Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Baylor University Medical Center, Dallas, Texas, United States

Farmington Health Center, Farmington, Utah, United States

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

South Jordan Health Center, South Jordan, Utah, United States

Sentara Martha Jefferson Hospital, Charlottesville, Virginia, United States

University of Virginia Cancer Center, Charlottesville, Virginia, United States

Sentara Leigh Hospital, Norfolk, Virginia, United States

Sentara Norfolk General Hospital, Norfolk, Virginia, United States

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Seattle Cancer Care Alliance, Seattle, Washington, United States

University of Washington Medical Center, Seattle, Washington, United States

ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States

Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States

University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States

ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States

ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States

Rwth Klinikum Aachen, Aachen, , Germany

Contact Details

Name: Christopher Comstock

Affiliation: ECOG-ACRIN Cancer Research Group

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: